Modus Therapeutics Holding AB receives preliminary approval for listing and publishes prospectus
STOCKHOLM, SWEDEN - 22 June 2021: Modus Therapeutics Holding AB (“Modus Therapeutics” or the “Company”) hereby announces that the Company has received preliminary approval for listing on Nasdaq First North Growth Market (“First North”). The Company hereby also publishes the prospectus in connection with the forthcoming issue of units (the “Listing Issue”), which initially amounts to a maximum of approximately SEK 33 million and in about a year a further maximum of approximately SEK 45 million that can be added to Modus Therapeutics through the warrant exercise. The subscription period for the